JPRN-UMIN000006305招募中1 期
Phase I/II study of TS-1 / Oxaliplatin / Radiation for KRAS mutation type locally advanced and recurrent rectal cancer. - Phase I/II study of TS-1 / Oxaliplatin / Radiation for KRAS mutation type locally advanced and recurrent rectal cancer.
Graduate School of Medicine, Osaka Univesity0 个研究点目标入组 31 人开始时间: 2011年10月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 31
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ. 2) No radiation therapy 3) Allergic to a drug 4) Patients under treatment with flucytosine. 5) Sensory neuropathy 6) Metastasis to CNS. 7) Intestinal paralysis or ileus 8) Massive pleural or abdominal effusion. 9) Active infection and inflammation. 10) Watery stools or diarrhea. 11) Severe complications 12) Pregnant or lactating 13) Other patients who are unfit for the study as determined by the attending physician.
研究者
相似试验
招募中
1 期
Phase I/II Study of TS-1/Oxaliplatin(SOX) for patients with unresectable advanced or recurrent gastric cancerunresectable advanced or recurrent gastric cancerJPRN-UMIN000015807Gunma University Graduate School of Medicine72
已完成
2 期
A multicenter phase II trial of TS-1+oxaliplatin+panitumumab as first-line treatment in patients with kras-wild type unresectable advanced colorectal liver metastasis.colorectal cancerJPRN-UMIN000007236Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences2
招募中
2 期
Phase II study of TS-1 / oxaliplatin(G-SOX) plus bevacizumab treatment for elderly advanced colorectal cancer patients.(GIANTS study)colorectal cancerJPRN-UMIN000009014niversity of Miyazaki Hospital.50
招募中
1 期
Phase I/II study of TS-1 / Oxaliplatin / Cetuximab / Radiation for KRAS wild type locally advanced and recurrent rectal cancer.advanced and recurrent rectal CancerJPRN-UMIN000006304Graduate School of Medicine, Osaka Univesity31
已完成
2 期
Phase II study of S-1 plus oxaliplatin (130 mg/m2, every 3 weeks) for advanced gastric cancerJPRN-UMIN000016973Shizuoka Cancer Center25